This protocol is judged by an institutional assessment board, an unbiased team that reviews any clinical trials involving human beings. If a analyze will involve a Schedule I drug, after the board approves the protocol as ethical, the researchers really need to submit an application for an investigational new drug (IND) range with the FDA.Therefore